Bayer Improves Therban HNBR Packaging

14 February 2000

Bayer Improves Therban HNBR Packaging

    AKRON, Ohio--Feb. 11, 2000--Bayer Corporation has improved the packaging for its Therban(R) products. The new Therban bale film wrap may be stripped or dispersed, depending on customer mixing conditions.
    The new film, with a melting range of 85 C to 110 C, presents a cost-effective option for customers able to disperse it. Film wrap that is dispersed requires no further handling, which can increase productivity, reduce waste and enhance worker safety.
    "Bayer has just provided another opportunity for our customers to benefit from waste reduction and increased productivity," says Brian McCue, Regional Product Manager, Therban. "Therban customers who have the ability to disperse the new film wrap can now realize improved cost savings."

    Other specs of Therban's new film wrap are as follows: ----------------------------------------------------------------------

Appearance Blue with white strip (16 cm wide) on one
    side. Product identification and bar coding
    are printed directly on the white strip. ---------------------------------------------------------------------- Thickness 2 mil (51 micron) ---------------------------------------------------------------------- Base polymer composition 18 wt % EVA/PE ---------------------------------------------------------------------- VICAT softening point 71 C ---------------------------------------------------------------------- Melt point 85 C ----------------------------------------------------------------------

    Therban HNBR, invented and patented by Bayer, gives products superior performance and durability in applications where extreme temperature, fuel, oil, ozone or abrasion exists.
    In August 1999, Bayer's Therban manufacturing unit in Orange, Texas, became the first and only HNBR facility in the world to be QS-9000 registered.
    Bayer Corporation is a research-based company with major businesses in health care and life sciences and chemicals. The company had 1998 sales of $8.1 billion and employs more than 23,000 people. Bayer Corporation is investing $15 billion in capital expenditures and research and development from 1995 through the year 2004. 1999 capital investment and R&D expenditures are projected to total $1.6 billion. Bayer Corporation, with headquarters in Pittsburgh, is a member of the worldwide Bayer Group, a $31 billion chemicals and health care group based in Leverkusen, Germany.